Advertisement

Supportive Care in Cancer

, Volume 24, Issue 10, pp 4105–4112 | Cite as

Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations

  • Isabelle Mahé
  • Didier Mayeur
  • Ivan Krakowski
Original Article

Abstract

Purpose

Venous thromboembolism (VTE) is one of the most frequent events associated with cancer, requiring hospitalization and generating additional healthcare costs. To date, no studies analyzing the additional costs resulting from VTE associated with cancer in France have been published. The objective of this study was to provide an estimation of the additional cost induced by VTE with cancer by analyzing hospital stays reported in the 2013 PMSI French Hospital Database (“Programme de Médicalisation des Systèmes d’Information”, a national hospital administrative database) for four cancer types (breast, lung, hepatocellular carcinoma, and colon).

Methods

The analysis is divided into three parts: a descriptive evaluation of hospitalizations for VTE with cancer, an analysis by severity level of diagnosis-related groups (DRG), and an estimation of the hospital costs based on the National Reference Costs (ENC). The French public ATIH (“Agence Technique de l’Information sur l’Hospitalisation”, a national Agency for Data on Hospital Care) database was used. The critical approach of this study is based on analysis of the distribution of stays according to levels of severity of DRG.

Results

A total of 14,251 hospitalizations were analyzed combining VTE and cancer. Hospitalizations of the two highest levels of severity (levels 3 and 4) for VTE with cancer represented 81.7 % of all hospitalizations in this population. Increased costs were seen for all four cancer types evaluated, with cost coefficients ranging from 1.34 to 2.01. For example, the average cost of lung cancer in cancer patients with VTE in the PMSI database was 7296 € versus 4647 € in the ATIH database. Cost coefficients were calculated, ranging from 1.34 in colon cancer, 1.50 for breast cancer, 1.57 in lung cancer, and 2.01 for hepatocellular carcinoma.

Conclusion

As discussed in the article, the current costs are high. Better physician adherence to clinical practice guidelines could potentially reduce these costs by lowering the number of recurrent VTE in patients with cancer.

Keywords

Cancer Economic burden Hospitalization Venous thromboembolism 

Notes

Acknowledgments

This work was supported by Pfizer PFE France, and remuneration was provided to authors.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715–722CrossRefPubMedGoogle Scholar
  2. 2.
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S–453SCrossRefPubMedGoogle Scholar
  3. 3.
    Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464CrossRefPubMedGoogle Scholar
  4. 4.
    Hanna N, Bikov KA, McNally D, Onwudiwe NC, Dalal M, Mullins CD (2012) Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer. Oncologist 17(9):1191–1197CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S–400SCrossRefPubMedGoogle Scholar
  6. 6.
    Thromboembolic Tisk Factors (THRIFT) Consensus Group (1992) Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 305:567–574Google Scholar
  7. 7.
    Cohen AT (2002) Discoveries in thrombosis care for medical patients. Semin Thromb Hemost 28(Suppl 3):13–17CrossRefPubMedGoogle Scholar
  8. 8.
    Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(no. 2):pp. 146–pp. 153CrossRefGoogle Scholar
  9. 9.
    Khorana AA, Dalal MR, Lin J, Connolly GC (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clin Outcomes Res CEOR 5:101–108CrossRefGoogle Scholar
  10. 10.
    Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488CrossRefPubMedGoogle Scholar
  11. 11.
    Yhim H-Y, Bang S-M (2014) Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism. Blood Res 49(2):77–79CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M, Investigators RIETE (2013) Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 131(1):24–30CrossRefPubMedGoogle Scholar
  13. 13.
    ANSM, “Recommandations de bonne pratique : Prévention et traitement de la maladie thrombo-embolique veineuse en médecine.” [Online]. Available: http://ansm.sante.fr/var/ansm_site/storage/original/application/ae4209ebc36d7164d4b7c876ddeaabab.pdf
  14. 14.
    “Standards, Options & Recommandations : Traitement curatif de la maladie thromboembolique veineuse chez les patients atteints de cancer et prévention et traitement des thromboses veineuses sur cathéter chez les patients atteints de cancer.” [Online]. Available: http://www.parhtage.sante.fr/re7/bre/doc.nsf/VDoc/171C92CDDFA303E6C125753D004B6C65/$FILE/C28_MVTE%20Oncologie_FNCLCC_2008.pdf
  15. 15.
    Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost JTH 11(no. 1):pp. 56–pp. 70CrossRefGoogle Scholar
  16. 16.
    Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S (2012) All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm JMCP 18(5):363–374PubMedGoogle Scholar
  17. 17.
    ATIH: rapport annuel 2014. Répartition des GHM par niveau de sévérité. http://www.atih.sante.fr/analyse-de-l-activite-hospitaliere-2014
  18. 18.
    Scotte F, Martelli N, Vainchtock A, Borget I (2015) The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France. Adv Ther 32(2):138–147CrossRefPubMedGoogle Scholar
  19. 19.
    Spyropoulos AC, Lin J (2007) Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm JMCP 13(6):475–486PubMedGoogle Scholar
  20. 20.
    Lang K, Patel AA, Munsell M, Bookhart BK, Mody SH, Schein JR, Menzin J (2015) Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis. J Thromb Thrombolysis 39(4):434–442CrossRefPubMedGoogle Scholar
  21. 21.
    Sevestre MA, Belizna C, Durant C, Bosson J-L, Vedrine L, Cajfinger F, Debourdeau P, Farge D, Carmen Investigators for the Groupe Francophone Thrombose et Cancer (GFTC) (2014) Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study. J Mal Vasc 39(3):161–168CrossRefPubMedGoogle Scholar
  22. 22.
    Huang W, Anderson FA, Rushton-Smith SK, Cohen AT (2015) Impact of thromboprophylaxis across the US acute care setting. PloS One 10(no. 3):p. e0121429CrossRefGoogle Scholar
  23. 23.
    Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, Müller L, Grunewald M, Stieler JM, Sinn M, Denecke T, Bischoff S, Oettle H, Dörken B, Riess H (2015) Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J Clin Oncol p. JCO.2014.55.1481Google Scholar
  24. 24.
    MacLellan DG, Richardson A, Stoodley MA (2012) Venous thromboembolism and cancer. ANZ J Surg 82(5):294–298CrossRefPubMedGoogle Scholar
  25. 25.
    Mahé I, Puget H, Buzzi JC, Lamuraglia M, Chidiac J, Strukov A, Helfer H, Perozziello A (2016) Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study. Support Care Cancer. doi: 10.1007/s00520-016-3164-8

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Isabelle Mahé
    • 1
    • 4
    • 5
  • Didier Mayeur
    • 2
    • 5
  • Ivan Krakowski
    • 3
    • 5
  1. 1.Internal Medicine DepartmentLouis Mourier Hospital, APHP, Paris 7 UniversityColombesFrance
  2. 2.Oncology DepartmentMignot HospitalLe Chesnay CedexFrance
  3. 3.Oncology Support Care DepartmentBergonié InstituteBordeaux CedexFrance
  4. 4.EA 7334 Université Paris Diderot, Sorbonne Paris CitéParisFrance
  5. 5.Intergroupe AFSOS-UNICANCERParisFrance

Personalised recommendations